Heterocyclic Compounds

Matches 1 - 50 out of 8,173	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 >

Document	Document Title
WO/2024/088189A1	MACROCYCLIC COMPOUND AS CDK9 INHIBITOR AND USE THEREOF The present disclosure provides a compound of formula (I), a pharmaceutical composition thereof, and a use thereof in treating and/or preventing diseases or disorders related to CDK9 kinase activity.
WO/2024/088407A1	NITROGEN-CONTAINING FUSED RING COMPOUND, INTERMEDIATE THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF Disclosed are a nitrogen-containing fused ring compound as shown in formula (I), an intermediate thereof, a preparation method therefor and the use thereof. The compound has a DNA polymerase θ inhibitory activity, and can be used for tr...
WO/2024/090469A1	FUSED PYRIDAZINE DERIVATIVE The present invention addresses the problem of providing a pharmaceutical composition, particularly a compound that is suitable for preventing and/or treating inflammatory diseases and/or neurodegenerative diseases.　The inventors of th...
WO/2024/046471A9	USP1 INHIBITOR The present application provides a class of novel compounds having a USP1 inhibitory activity as shown in formula (II'), pharmaceutical compositions comprising the compounds, useful intermediates for preparing the compounds, and a method...
WO/2024/082959A1	FLUORESCENT [1,2,3]TRIAZOLO[4,5-F]-2,1,3-BENZOTHIADIAZOLE DERIVATIVES FOR ACCELERATED CANCER THERANOSTIC The present invention discloses aggregation-induced emission fluorescent compounds with near-infrared (NIR) emission. This fluorescent compound is then encapsulated by polymer matrix to yield nanoaggregates which is confirmed to show an ...
WO/2024/083980A1	BICYCLIC FERROPORTIN INHIBITORS The invention relates to novel compounds of the general formula (I-A) as defined in the application and pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the use as ferroportin inhibitors, ...
WO/2024/086252A1	NOVEL ATP-SENSITIVE POTASSIUM CHANNEL POTENTIATORS, THEIR PREPARATION AND USE The present disclosure relates to compounds of general formula (I) or a pharmaceutically acceptable salt, solvate and/or hydrate thereof, methods for their preparation, the use of said compounds for use as a medicament, and their use in ...
WO/2024/086634A1	HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS The application relates to heterocyclic heteroaromatic macrocyclic ether compounds of the general Formula (I), pharmaceutically acceptable salts of the compounds and pharmaceutical compositions thereof. The compounds act as selective inh...
WO/2024/083223A1	MACROCYCLIC COMPOUNDS AND MEDICAL USE THEREOF The present disclosure relates to macrocyclic compounds and the medical use thereof, the structures of the macrocyclic compounds being represented as formula (I). The present disclosure also relates to a method for preparing the compound...
WO/2024/082958A1	FLUORESCENT [1,2,3]TRIAZOLO[4,5-F]-2,1,3-BENZOTHIADIAZOLE DERIVATIVES FOR PHOTOTHERMAL CANCER THERANOSTIC The present invention discloses aggregation-induced emission fluorescent compounds with near-infrared (NIR) emission. The present invention also shows application for imaging-guided phototheranostic with the integration of both photodyna...
WO/2024/077391A1	THIAZOLO[5,4-D]PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF Compounds, compositions and their use in the treatment of a proliferative disease or condition such as a said proliferative disease or disorder associated with a RAF gene mutation and/or a RAS gene mutation. The compounds disclosed are o...
WO/2024/076300A1	COMPOUNDS USEFUL IN MODULATION OF AHR SIGNALLING Compounds of the general formula (I) as described and defined herein, in particular compounds of formula (II), methods for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of sa...
WO/2024/075696A1	IMIDAZOPYRIDINE DERIVATIVES WITH BICYCLIC STRUCTURE The present invention addresses the problem of providing a novel compound having an SMG1 inhibitory activity and an anticancer effect, or a pharmaceutically acceptable salt thereof etc.　A compound represented by formula (1) or a pharma...
WO/2024/073658A1	HYDANTOIN MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION The subject matter described herein is directed to myelin-promoting compounds of Formula (I) and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of admin...
WO/2024/071398A1	ABHD6 ANTAGONIST The purpose of the present invention is to provide a drug for the prevention and/or treatment of diseases associated with ABHD6, said drug containing a compound having ABHD6 inhibitory activity as an active ingredient. A compound represe...
WO/2024/072794A1	PYRIDINE CARBOXAMIDE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS The invention provides pyridine carboxamide compounds, pharmaceutical compositions, and their use in treating medical conditions.
WO/2024/060966A1	PAN-KRAS INHIBITOR COMPOUND The present invention relates to a pan-KRAS inhibitor compound represented by formula (I), a pharmaceutical composition comprising the compound, and use of the compound of formula (I) in preventing and/or treating cancers, tumors, inflam...
WO/2024/061298A1	SOLID FORM OF HETEROCYCLO-SUBSTITUTED METHANONE DERIVATIVE AND USE THEREOF The present invention relates to a heterocyclo-substituted methanone derivative and the use thereof. In particular, the present invention provides a solid form of (S)-(3-amino-5-(1-amino-1,3-dihydrospiro[indene-2,4'-piperid in]-1'-yl)pyr...
WO/2024/057021A1	COMPOUNDS FOR TARGETED PROTEIN DEGRADATION The present disclosure relates to a novel class of bifunctional molecules that are useful in a targeted or selective degradation of a protein.
WO/2024/059563A1	CYCLIC SULFONAMIDE RIBONUCLEOTIDE REDUCTASE (RNR) INHIBITORS AND USES THEREOF Provided herein are compounds and methods for the treatment of cancer. The methods include administering to a subject in need a therapeutically effective amount of a cyclic sulfonamide RNR inhibitor disclosed herein.
WO/2024/055196A1	A-D-A TYPE ORGANIC COMPOUND AND PREPARATION METHOD THEREFOR The present invention relates to an acceptor-donor-acceptor (A-D-A) type organic compound and a preparation method therefor. The material has a thermal activation delayed fluorescence property; a monomolecular structure presents a face-t...
WO/2024/059010A1	COMPOUNDS FOR TREATING CANCER The present application relates to compounds of Formula (A), as defined herein, and pharmaceutically acceptable salts thereof, as well as processes for preparing compounds of Formula (A), and pharmaceutically acceptable salts thereof. Th...
WO/2024/059798A1	THIAZOLOTHIAZOLE COMPOSITE MATERIALS AND METHODS EMPLOYING THE SAME A composite material, comprising one or more thiazolothiazole (TTz) compounds and one or more matrix materials is described herein. In another aspect, a sensor comprising a composite material comprising one or more thiazolothiazole (TTz)...
WO/2024/059524A1	PYRAZOLYLCARBOXAMIDE COMPOUNDS AND THEIR USE IN THERAPY The invention provides pyrazolylcarboxamide compounds, pharmaceutical compositions, their use for inhibiting mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1), and their use in the treatment of a disease or condi...
WO/2024/054851A1	MACROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USING THEREOF The present disclosure includes, among other things, macrocyclic CFTR modulators of formula I, pharmaceutical compositions, and methods of making and using the same.
WO/2024/054840A1	MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF The present disclosure includes, among other things, compounds of formula I (I) as CFTR modulators, pharmaceutical compositions, and methods of making and using the same.
WO/2024/051778A1	COMPOUNDS, PREPARATION METHODS AND USES THEREOF Provided herein are compounds having a Formula II-4, or a pharmaceutically acceptable salt thereof. Also provided herein are methods of preparing the compounds and methods of using the compounds in inhibiting PI3K in a cell, or in treati...
WO/2024/051784A1	NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF Provided are a nitrogen-containing heterocyclic compound, a pharmaceutical composition thereof, and use thereof. The structure of the nitrogen-containing heterocyclic compound is represented by formula I. The nitrogen-containing heterocy...
WO/2024/053350A1	METHOD FOR PRODUCING AMINOAZIDE COMPOUND, DIAMINE COMPOUND, AND EDOXABAN The purpose of the present invention is to provide a method for producing an aminoazide compound and a diamine compound in which the formation of undesired diastereomers is inhibited and which has good diastereoselectivity. Provided is a...
WO/2024/051702A1	COMPOUND USED AS INHIBITOR OF CDK4 KINASE AND USE THEREOF The present invention relates to a compound used as an inhibitor of a CDK4 kinase and use thereof. Specifically, the compound of the present invention has a structure represented by formula (I), wherein the definitions of each group and ...
WO/2024/050809A1	METHOD FOR GLYCOSYLATION MODIFICATION OF PROTEINS AND/OR POLYPEPTIDES Provided is a method for the glycosylation modification of proteins and/or polypeptides, belonging to the technical field of medicinal chemistry. Using glycosyl sulfinate as a raw material, a method for the glycosylation modification of ...
WO/2024/046471A1	USP1 INHIBITOR The present application provides a class of novel compounds having a USP1 inhibitory activity as shown in formula (II'), pharmaceutical compositions comprising the compounds, useful intermediates for preparing the compounds, and a method...
WO/2024/050370A1	HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF The present disclosure relates to compounds of Formula (I): and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are usef...
WO/2024/049760A1	CYCLIC UREA THIAZOLYL COMPOUNDS FOR TREATMENT OF HSV The present disclosure provides, in part, cyclic urea thiazolyl compounds, and pharmaceutical compositions thereof, and methods of the treatment and prophylaxis of HSV infections.
WO/2024/046361A1	AZEPINE FUSED RING COMPOUND AS RIPK1 INHIBITOR AND USE THEREOF The present disclosure provides a compound of formula (I), a pharmaceutical composition thereof, and a use thereof in treating and/or preventing diseases or conditions related to the activity of RIPK1 kinase.
WO/2024/044713A1	NAPHTHYRIDINE COMPOUNDS FOR INHIBITION OF RAF KINASES The present disclosure relates to compounds and compositions for inhibition of RAF serine/threonine protein kinases, methods of preparing said compounds and compositions, and their use in the treatment of various cancers.
WO/2024/042961A1	COMPOUND, COMPOSITION, FILM, LAMINATE, AND DISPLAY DEVICE Provided is a compound represented by formula (1). In formula (1), Ar11, Ar12, and Ar13 represent a 1,4-phenylene group, a 1,4-naphthylene group, or a divalent aromatic condensed heterocyclic group having two five-membered rings, and at ...
WO/2024/040190A1	INDANE AND COUMARAN DERIVATIVES AS FAST SKELETAL MUSCLE MYOSIN INHIBITORS Provided are compounds of Formula (I). Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formu...
WO/2024/033845A1	HETEROCYCLIC COMPOUND The invention provides a compound of Formula (I), or a pharmaceutically acceptable salt thereof, or a solvate thereof, or a hydrate thereof:, wherein X, Y, R1, R2, R3, R4, R5, and R6 are as defined in the specification, for treatment of ...
WO/2024/035627A1	HETEROCYCLIC AMIDE AND UREA COMPOUNDS AS JAK2 INHIBITORS The present disclosure provides heterocyclic amide and urea compounds and compositions thereof useful for inhibiting JAK2.
WO/2024/032569A1	PRODRUG COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF The present invention provides a prodrug compound, a preparation method therefor and a use thereof. Specifically, the present invention provides a compound represented by formula (I), a preparation method therefor, and a use thereof as a...
WO/2024/032410A1	COMPOSITION OF PIPERAZINE COMPOUND AND PD-1 INHIBITOR OR PD-L1 INHIBITOR AND USE THEREOF IN TREATING TUMORS The present application relates to a combination of a piperazine compound and a PD-1 inhibitor antibody or a PD-L1 inhibitor antibody and use thereof in treating tumors.
WO/2024/031753A1	INDOLINE COMPOUND AND PREPARATION METHOD THEREFOR The present invention provides a preparation method for an indoline compound. The indoline compound is prepared by conducting a cyclization rearrangement reaction of N-arylsulfonyl-2-β,γ-unsaturated olefin-substituted aniline by means ...
WO/2024/031089A1	SARS-COV2 MAIN PROTEASE INHIBITORS The present disclosure relates to compounds of Formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, useful in the treatment of treating viral infections, for example, coronaviridae infections.
WO/2024/030908A1	MULTI-CYCLIC IRAK1 AND IRAK4 INHIBITING COMPOUNDS AND USES THEREOF The present disclosure provides a method of treating an inflammatory disease/disorder, acute myeloid leukemia (AML), or myelodysplastic syndrome (MDS) in a subject comprising administering to the subject a compound that inhibits IRAKI an...
WO/2024/023727A1	NOVEL ACC INHIBITORS A compound having the structures: Formulae (Ia) or (Ib) or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or pharmaceutically acceptable salt, wherein; R selected from the group cons...
WO/2024/022286A1	MACROCYCLIC EGFR INHIBITOR, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF The present invention relates to a macrocyclic EGFR inhibitor and a preparation method therefor and the pharmaceutical use thereof. In particular, the present invention relates to an EGFR inhibitor having a structure of formula (I), a ph...
WO/2024/017859A1	MACROCYCLE COMPOUNDS FOR THE TREATMENT OF CANCER The present invention relates to compounds of formula (I), wherein R1 to R7, A1 and A2 are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the compounds.
WO/2024/011414A1	REACTION METHOD FOR SECONDARY AMINE AND O-DIIODOBENZENE Disclosed in the present invention is a reaction method for secondary amine and o-diiodobenzene, comprising: reacting secondary amine with o-diiodobenzene in the presence of an alkali metal hydride or a Grignard reagent to complete the r...
WO/2024/015497A1	TYROSINE KINASE 2 INHIBITORS AND USES THEREOF This disclosure relates to compounds of Formula (I) or pharmaceutically acceptable salts thereof, in which all of the variables in Formula (I) are as defined in the application. The compounds of this disclosure are capable of inhibiting ...

Matches 1 - 50 out of 8,173	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 >